PURPOSE: Early assessment of tumor response to therapy is vital for treatment optimization for the individual cancer patient. Induction of apoptosis is an early and nearly universal effect of anticancer therapies. The purpose of this study was to assess the performance of (18)F-ML-10, a novel PET radiotracer for apoptosis, as a tool for the early detection of response of brain metastases to whole-brain radiation therapy (WBRT). MATERIALS AND METHODS: Ten patients with brain metastases treated with WBRT at 30 Gy in ten daily fractions were enrolled in this trial. Each patient underwent two (18)F-ML-10 PET scans, one prior to the radiation therapy (baseline scan), and the second after nine or ten fractions of radiotherapy (follow-up scan). MRI was performed at 6-8 weeks following completion of the radiation therapy. Early treatment-induced changes in tumor (18)F-ML-10 uptake on the PET scan were measured by voxel-based analysis, and were then evaluated by correlation analysis as predictors of the extent of later changes in tumor anatomical dimensions as seen on MRI scans 6-8 weeks after completion of therapy. RESULTS: In all ten patients, all brain lesions were detected by both MRI and the (18)F-ML-10 PET scan. A highly significant correlation was found between early changes on the (18)F-ML-10 scan and later changes in tumor anatomical dimensions (r = 0.9). CONCLUSION: These results support the potential of (18)F-ML-10 PET as a novel tool for the early detection of response of brain metastases to WBRT.
PURPOSE: Early assessment of tumor response to therapy is vital for treatment optimization for the individual cancerpatient. Induction of apoptosis is an early and nearly universal effect of anticancer therapies. The purpose of this study was to assess the performance of (18)F-ML-10, a novel PET radiotracer for apoptosis, as a tool for the early detection of response of brain metastases to whole-brain radiation therapy (WBRT). MATERIALS AND METHODS: Ten patients with brain metastases treated with WBRT at 30 Gy in ten daily fractions were enrolled in this trial. Each patient underwent two (18)F-ML-10 PET scans, one prior to the radiation therapy (baseline scan), and the second after nine or ten fractions of radiotherapy (follow-up scan). MRI was performed at 6-8 weeks following completion of the radiation therapy. Early treatment-induced changes in tumor (18)F-ML-10 uptake on the PET scan were measured by voxel-based analysis, and were then evaluated by correlation analysis as predictors of the extent of later changes in tumor anatomical dimensions as seen on MRI scans 6-8 weeks after completion of therapy. RESULTS: In all ten patients, all brain lesions were detected by both MRI and the (18)F-ML-10 PET scan. A highly significant correlation was found between early changes on the (18)F-ML-10 scan and later changes in tumor anatomical dimensions (r = 0.9). CONCLUSION: These results support the potential of (18)F-ML-10 PET as a novel tool for the early detection of response of brain metastases to WBRT.
Authors: Minesh P Mehta; May N Tsao; Timothy J Whelan; David E Morris; James A Hayman; John C Flickinger; Michael Mills; C Leland Rogers; Luis Souhami Journal: Int J Radiat Oncol Biol Phys Date: 2005-09-01 Impact factor: 7.038
Authors: Subbareddy Maddika; Sudharsana Rao Ande; Soumya Panigrahi; Ted Paranjothy; Kazimierz Weglarczyk; Anne Zuse; Mehdi Eshraghi; Kamala D Manda; Emilia Wiechec; Marek Los Journal: Drug Resist Updat Date: 2007-02-14 Impact factor: 18.500
Authors: Craig J Galbán; Thomas L Chenevert; Charles R Meyer; Christina Tsien; Theodore S Lawrence; Daniel A Hamstra; Larry Junck; Pia C Sundgren; Timothy D Johnson; Stefanie Galbán; Judith S Sebolt-Leopold; Alnawaz Rehemtulla; Brian D Ross Journal: Clin Cancer Res Date: 2011-04-28 Impact factor: 12.531
Authors: Quang-Dé Nguyen; Graham Smith; Matthias Glaser; Meg Perumal; Erik Arstad; Eric O Aboagye Journal: Proc Natl Acad Sci U S A Date: 2009-09-03 Impact factor: 11.205
Authors: Shannon Puhalla; William Elmquist; David Freyer; Lawrence Kleinberg; Chris Adkins; Paul Lockman; John McGregor; Leslie Muldoon; Gary Nesbit; David Peereboom; Quentin Smith; Sara Walker; Edward Neuwelt Journal: Neuro Oncol Date: 2015-05 Impact factor: 12.300
Authors: S Dizdarevic; R McCready; J F C Turner; M C Bagley; P Blower; P Schmid; G Flux; A Hall; I Ziv Journal: Eur J Nucl Med Mol Imaging Date: 2014-02-25 Impact factor: 9.236
Authors: Matthew J Oborski; Charles M Laymon; Yongxian Qian; Frank S Lieberman; Arden D Nelson; James M Mountz Journal: Transl Oncol Date: 2014-02-01 Impact factor: 4.243
Authors: Willem Grootjans; Lioe-Fee de Geus-Oei; Esther G C Troost; Eric P Visser; Wim J G Oyen; Johan Bussink Journal: Nat Rev Clin Oncol Date: 2015-04-28 Impact factor: 66.675
Authors: Matthew R Hight; Yiu-Yin Cheung; Michael L Nickels; Eric S Dawson; Ping Zhao; Samir Saleh; Jason R Buck; Dewei Tang; M Kay Washington; Robert J Coffey; H Charles Manning Journal: Clin Cancer Res Date: 2014-02-26 Impact factor: 12.531